WASHINGTON, Sept 30 (Reuters) - U.S. drugmaker Pfizer ( PFE )

will not be subject to "Section 232" pharmaceutical

tariffs if it moves production to the U.S. during a three-year

grace period, CEO Albert Bourla told reporters.

Bourla spoke in an Oval Office event with U.S. President

Donald Trump at the White House after striking a deal with his

administration on drug prices.